Your browser doesn't support javascript.
loading
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma.
Spasevska, Ivana; Sharma, Ankush; Steen, Chloé B; Josefsson, Sarah E; Blaker, Yngvild N; Kolstad, Arne; Rustad, Even H; Meyer, Saskia; Isaksen, Kathrine; Chellappa, Stalin; Kushekhar, Kushi; Beiske, Klaus; Førsund, Mette S; Spetalen, Signe; Holte, Harald; Østenstad, Bjørn; Brodtkorb, Marianne; Kimby, Eva; Olweus, Johanna; Taskén, Kjetil; Newman, Aaron M; Lorenz, Susanne; Smeland, Erlend B; Alizadeh, Ash A; Huse, Kanutte; Myklebust, June H.
Afiliación
  • Spasevska I; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Sharma A; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.
  • Steen CB; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.
  • Josefsson SE; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Blaker YN; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.
  • Kolstad A; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.
  • Rustad EH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Meyer S; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.
  • Isaksen K; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.
  • Chellappa S; Division of Oncology, Stanford University School of Medicine, Stanford, CA.
  • Kushekhar K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Beiske K; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.
  • Førsund MS; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Spetalen S; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.
  • Holte H; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.
  • Østenstad B; Department of Oncology, Innlandet Hospital Trust, Lillehammer, Norway.
  • Brodtkorb M; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Kimby E; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Olweus J; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.
  • Taskén K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Newman AM; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.
  • Lorenz S; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Smeland EB; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.
  • Alizadeh AA; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.
  • Huse K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Myklebust JH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Blood Adv ; 7(23): 7216-7230, 2023 12 12.
Article en En | MEDLINE | ID: mdl-37695745
ABSTRACT
Tumor-infiltrating regulatory T cells (Tregs) contribute to an immunosuppressive tumor microenvironment. Despite extensive studies, the prognostic impact of tumor-infiltrating Tregs in B-cell non-Hodgkin lymphomas (B-NHLs) remains unclear. Emerging studies suggest substantial heterogeneity in the phenotypes and suppressive capacities of Tregs, emphasizing the importance of understanding Treg diversity and the need for additional markers to identify highly suppressive Tregs. Here, we applied single-cell RNA sequencing and T-cell receptor sequencing combined with high-dimensional cytometry to decipher the heterogeneity of intratumoral Tregs in diffuse large B-cell lymphoma and follicular lymphoma (FL), compared with that in nonmalignant tonsillar tissue. We identified 3 distinct transcriptional states of Tregs resting, activated, and unconventional LAG3+FOXP3- Tregs. Activated Tregs were enriched in B-NHL tumors, coexpressed several checkpoint receptors, and had stronger immunosuppressive activity compared with resting Tregs. In FL, activated Tregs were found in closer proximity to CD4+ and CD8+ T cells than other cell types. Furthermore, we used a computational approach to develop unique gene signature matrices, which were used to enumerate each Treg subset in cohorts with bulk gene expression data. In 2 independent FL cohorts, activated Tregs was the major subset, and high abundance was associated with adverse outcome. This study demonstrates that Tregs infiltrating B-NHL tumors are transcriptionally and functionally diverse. Highly immunosuppressive activated Tregs were enriched in tumor tissue but absent in the peripheral blood. Our data suggest that a deeper understanding of Treg heterogeneity in B-NHL could open new paths for rational drug design, facilitating selective targeting to improve antitumor immunity.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma Folicular / Linfoma de Células B Grandes Difuso Límite: Humans Idioma: En Revista: Blood Adv Año: 2023 Tipo del documento: Article País de afiliación: Noruega

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma Folicular / Linfoma de Células B Grandes Difuso Límite: Humans Idioma: En Revista: Blood Adv Año: 2023 Tipo del documento: Article País de afiliación: Noruega